MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.

ClinicalTrials.gov ID: NCT02616250

Public ClinicalTrials.gov record NCT02616250. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy and Safety of Ivermectin 1% Topical Cream Associated With Brimonidine 0.33% Topical Gel in the Treatment of Moderate to Severe Rosacea

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM) associated with Brimonidine 0.33% gel (Br) compared with the association of their respective vehicles in the treatment of moderate to severe rosacea.

Study identification

NCT ID: NCT02616250
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Galderma R&D; Industry
Enrollment: 190 participants

Conditions and interventions

Conditions

Rosacea

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2015 (Type not available)
Primary completion: Sep 2016 (Actual)
Completion: Sep 2016 (Actual)
Last update posted: Feb 18, 2021

2015 – 2016

United States locations

U.S. sites: 7
U.S. states: 6
U.S. cities: 7

Facility	City	State	ZIP	Site status
Not listed	Fort Smith	Arkansas	—	—
Not listed	Rogers	Arkansas	—	—
Not listed	Sacramento	California	—	—
Not listed	Orlando	Florida	—	—
Not listed	Omaha	Nebraska	—	—
Not listed	New York	New York	—	—
Not listed	Pflugerville	Texas	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02616250, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 18, 2021 · Synced Oct 22, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02616250 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →